Head of Commercial Operations Pelago Bioscience, Stockholms Lan, Sweden
Confirmation of target engagement in relevant physiological environment ensures successful drug discovery and the right project prioritization. By applying CETSA®, you can make better and more informed decisions at earlier stages in your drug discovery projects. Welcome to learn from the Pelago Bioscience Team on recent developments including:
CETSA® Navigate MS – A targeted proteomics approach for assessment of target engagement of compounds against a target proteins without the requirements of detection antibodies.
CETSA® Navigate HT – A paradigm shift in lead generation, an efficient approach for identifying small molecule binders to challenging targets in true physiological settings.
CETSA® Explore – Unbiased proteome-wide target identification for target deconvolution, selectivity assessments, elucidation of the molecular MoA and biomarker discovery.
.jpeg.jpg "Stina Lundgren, n/a (she/her/hers) photo")